HEOR Publications HEOR resources

BeOne Medicines, formerly known as BeiGene, is committed to developing transparent, actionable clinical and health economic information.

The publications below have been presented at international meetings and congresses, including AMCP, ISPOR, ASH, ASCO, and ESMO.

These publications may contain information about unapproved uses of or indications for products or investigational drugs that have not received FDA approval in the United States.

Click the VIEW buttons below to access additional publications.

Recurrent Patient-Reported Outcome-Based Symptomatic Deterioration Predicts Progression-Free Survival: Results From RATIONALE-305

Presented at:

European Society for Medical Oncology (ESMO); September 13-17, 2024; Barcelona, Spain

View

Comparative Efficacy and Safety of Tislelizumab Versus Anti-PD-1 Treatments in Second Line Esophageal Squamous Cell Carcinoma: Simulated Treatment Comparisons

Presented at:

European Society for Medical Oncology (ESMO); September 13-17, 2024; Barcelona, Spain

View

Zanubrutinib Versus Acalabrutinib in B-cell Malignancies: An Adverse Event-Based Economic Analysis

Presented at:

European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain

View

Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis

Presented at:

European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain

View

By accessing this page, you acknowledge that the information provided is intended for individuals and entities seeking health care economic information (HCEI) to inform population-based health care decisions and is not a source of medical advice.